FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

BÜHLMANN Quantum Blue® fCAL Citation:

Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663.

Highlight from this Publication

“The FC test effected a change in management 51.3% of the time and receipt of the result was associated with a reduction in the number of colonoscopies performed.”

General Highlights from this Publication:

  1. Evaluation of the perspectives of gastroenterologists on use of fecal caloprotectin (FC) and the impact on management of subjects with inflammatory bowel disease (IBD)
  2. Outcomes stratified to FC test results
  3. Significance of FC testing
  4. Use of BÜHLMANN’s  Quantum Blue® fCAL for measuring FC levels in all stool samples
  5. Potential of FC to generate cost savings
Quantum Blue® fCAL are for Research Use Only. Not for use in diagnostic procedures in the US.
Quantum Blue ® fCAL: Health Canada License: 83477